chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Calcium ionised normal, Computerised tomogram head normal, Dizziness, Electrocardiogram normal, Full blood count normal
Clinical narrative: Per patient history, 3 days after receiving 1st dose of Pfizer COVID vaccine she developed left arm redness, bumpy rash and swelling. While the rash resolved over time, she continues to have mild waxing/waning swelling of her left arm from upper arm down to wrist, which she reports in November 2021.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Gait disturbance, Metabolic function test normal, Paraesthesia, Thyroxine free normal, Troponin normal
Clinical narrative: Per patient history, 3 days after receiving 1st dose of Pfizer COVID vaccine she developed left arm redness, bumpy rash and swelling. While the rash resolved over time, she continues to have mild waxing/waning swelling of her left arm from upper arm down to wrist, which she reports in November 2021.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Urine analysis normal
Clinical narrative: Per patient history, 3 days after receiving 1st dose of Pfizer COVID vaccine she developed left arm redness, bumpy rash and swelling. While the rash resolved over time, she continues to have mild waxing/waning swelling of her left arm from upper arm down to wrist, which she reports in November 2021.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Balance disorder, Chills, Dizziness, Dysstasia, Ear disorder
Clinical narrative: Per patient history, 3 days after receiving 1st dose of Pfizer COVID vaccine she developed left arm redness, bumpy rash and swelling. While the rash resolved over time, she continues to have mild waxing/waning swelling of her left arm from upper arm down to wrist, which she reports in November 2021.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Erythema, Eye disorder, Feeling of body temperature change, Hypoacusis, Hypoaesthesia
Clinical narrative: Per patient history, 3 days after receiving 1st dose of Pfizer COVID vaccine she developed left arm redness, bumpy rash and swelling. While the rash resolved over time, she continues to have mild waxing/waning swelling of her left arm from upper arm down to wrist, which she reports in November 2021.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Influenza, Musculoskeletal stiffness, Nausea, Paraesthesia, Peripheral swelling
Clinical narrative: Per patient history, 3 days after receiving 1st dose of Pfizer COVID vaccine she developed left arm redness, bumpy rash and swelling. While the rash resolved over time, she continues to have mild waxing/waning swelling of her left arm from upper arm down to wrist, which she reports in November 2021.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Presyncope, Rash, Sensory disturbance, Tinnitus, Vaginal haemorrhage
Clinical narrative: Per patient history, 3 days after receiving 1st dose of Pfizer COVID vaccine she developed left arm redness, bumpy rash and swelling. While the rash resolved over time, she continues to have mild waxing/waning swelling of her left arm from upper arm down to wrist, which she reports in November 2021.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Vestibular disorder
Clinical narrative: Per patient history, 3 days after receiving 1st dose of Pfizer COVID vaccine she developed left arm redness, bumpy rash and swelling. While the rash resolved over time, she continues to have mild waxing/waning swelling of her left arm from upper arm down to wrist, which she reports in November 2021.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Erythema, Peripheral swelling, Rash, Rash papular, Ultrasound Doppler normal
Clinical narrative: Per patient history, 3 days after receiving 1st dose of Pfizer COVID vaccine she developed left arm redness, bumpy rash and swelling. While the rash resolved over time, she continues to have mild waxing/waning swelling of her left arm from upper arm down to wrist, which she reports in November 2021.
Age: 82.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Deep vein thrombosis
Clinical narrative: Severe swelling of both legs/feet; Severe swelling of both legs/feet; Weakness; tired; unsteady when walk; This is a spontaneous report from a contactable consumer. This 82-year-old female consumer (patient) reported that:  A 82-years-old non-pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Batch/Lot Number: ER8732) via an unspecified route of administration in arm left on 31Mar2021 14:00 (at the age of 82-year-old) as DOSE 2, SINGLE for COVID-19 immunization at Public Health Clinic/Veterans Administration facility. Medical history included May-Thurner Symptom Blood Clot from 2011 to an unknown date. Patient had known allergies of sulfa drugs and levaquin. Concomitant medications included citalopram (CITALOPRAM) taken 200 mg, cetirizine hydrochloride (CETRIZINE) taken 10 mg, acetaminophen (ACETAMINOPHEN, PM) and taken medications within 2 weeks of vaccination. Patient didn't receive any other vaccine within four weeks of vaccination. The patient was not diagnosed with COVID-19 prior to vaccination. The patient was not tested for COVID-19 post vaccination. The patient previously received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Batch/Lot Number: EN6207) via an unspecified route of administration in arm left on unknown date as DOSE 1, SINGLE for COVID-19 immunization. On 11Apr2021 at 09:30 AM patient experienced severe swelling of both legs/feet, weakness, tired, unsteady when walk. Therapeutic measures were taken as a result of severe swelling of both legs/feet, weakness, tired, unsteady when walk with furosemide 40 mg. Adverse event resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the event was not recovered.   No follow-up attempts are possible. No further information is expected.
Age: 82.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Asthenia, Fatigue, Gait disturbance, Peripheral swelling
Clinical narrative: Severe swelling of both legs/feet; Severe swelling of both legs/feet; Weakness; tired; unsteady when walk; This is a spontaneous report from a contactable consumer. This 82-year-old female consumer (patient) reported that:  A 82-years-old non-pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Batch/Lot Number: ER8732) via an unspecified route of administration in arm left on 31Mar2021 14:00 (at the age of 82-year-old) as DOSE 2, SINGLE for COVID-19 immunization at Public Health Clinic/Veterans Administration facility. Medical history included May-Thurner Symptom Blood Clot from 2011 to an unknown date. Patient had known allergies of sulfa drugs and levaquin. Concomitant medications included citalopram (CITALOPRAM) taken 200 mg, cetirizine hydrochloride (CETRIZINE) taken 10 mg, acetaminophen (ACETAMINOPHEN, PM) and taken medications within 2 weeks of vaccination. Patient didn't receive any other vaccine within four weeks of vaccination. The patient was not diagnosed with COVID-19 prior to vaccination. The patient was not tested for COVID-19 post vaccination. The patient previously received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Batch/Lot Number: EN6207) via an unspecified route of administration in arm left on unknown date as DOSE 1, SINGLE for COVID-19 immunization. On 11Apr2021 at 09:30 AM patient experienced severe swelling of both legs/feet, weakness, tired, unsteady when walk. Therapeutic measures were taken as a result of severe swelling of both legs/feet, weakness, tired, unsteady when walk with furosemide 40 mg. Adverse event resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the event was not recovered.   No follow-up attempts are possible. No further information is expected.
Age: 52.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Asthenia, Chills, Dizziness, Vomiting
Clinical narrative: The next early morning after the vaccination I had vertigo that is still on going and when I don't have vertigo I constantly stay dizzy and I feel vibration on both of my eyes, I feel vibration on my eyes during my sleep, These symptoms I have never experience in my life. Everything started the morning after the vaccination. It has reduced with timing, but it has not gone away completely. I decided to get checked a month after these symptoms due to the pandemic and not having enough health care from doctors.
Age: 52.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Computerised tomogram, Dizziness, Ocular discomfort, Vertigo
Clinical narrative: The next early morning after the vaccination I had vertigo that is still on going and when I don't have vertigo I constantly stay dizzy and I feel vibration on both of my eyes, I feel vibration on my eyes during my sleep, These symptoms I have never experience in my life. Everything started the morning after the vaccination. It has reduced with timing, but it has not gone away completely. I decided to get checked a month after these symptoms due to the pandemic and not having enough health care from doctors.
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Suspected COVID-19, Vaccination failure
Clinical narrative: METAL TASTE IN MOUTH; SUSPECTED CLINICAL VACCINATION FAILURE; SUSPECTED COVID-19 INFECTION; This spontaneous report received from a patient via a company representative via social media concerned a male of unspecified age, race and ethnic origin. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown and expiry: Unknown) dose was not reported, (Dose Number in Series: 1), 1 total administered on MAY-2021 for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported.  On JUL-2021, the patient experienced suspected clinical vaccination failure and suspected covid-19 infection. On an unspecified date, the patient experienced metal taste in mouth. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the metal taste in mouth, suspected clinical vaccination failure and suspected covid-19 infection was not reported. This report was serious (Other Medically Important Condition). This report was associated with product quality complaint: 90000203790 This case, from the same reporter is linked to 20211152802.; Sender's Comments: V0: 20211152440-COVID-19 VACCINE AD26.COV2.S-Suspected clinical vaccination failure. This event is considered not related. The event has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There are other factors more likely to be associated with the event than the drug. Specifically: SPECIAL SITUATIONS
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Dysgeusia, Suspected COVID-19, Vaccination failure
Clinical narrative: METAL TASTE IN MOUTH; SUSPECTED CLINICAL VACCINATION FAILURE; SUSPECTED COVID-19 INFECTION; This spontaneous report received from a patient via a company representative via social media concerned a male of unspecified age, race and ethnic origin. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown and expiry: Unknown) dose was not reported, (Dose Number in Series: 1), 1 total administered on MAY-2021 for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported.  On JUL-2021, the patient experienced suspected clinical vaccination failure and suspected covid-19 infection. On an unspecified date, the patient experienced metal taste in mouth. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the metal taste in mouth, suspected clinical vaccination failure and suspected covid-19 infection was not reported. This report was serious (Other Medically Important Condition). This report was associated with product quality complaint: 90000203790 This case, from the same reporter is linked to 20211152802.; Sender's Comments: V0: 20211152440-COVID-19 VACCINE AD26.COV2.S-Suspected clinical vaccination failure. This event is considered not related. The event has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There are other factors more likely to be associated with the event than the drug. Specifically: SPECIAL SITUATIONS
Age: 11.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: GUARDIAN LISTED PATIENT'S DATE OF BIRTH AS INCORRECT ON THE VACCINE SCREENING FORM, RATHER THAN THEIR ACTUAL BIRTHDAY. SO PATIENT WAS AGE 11 AT TIME OF VACCINATION.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Anti-thyroid antibody positive, Antinuclear antibody positive, Blood thyroid stimulating hormone, Glycosylated haemoglobin, Hypoaesthesia
Clinical narrative: Developed paresthesias (numbness and tingling). Initially in the right arm x 1 day on 4/1. Subsequently developed more persistent parestheias in the right lower extremity on 4/14. Had similar lower extremity paresthesias in the past, but these were brief and never persisted. Over the next week developed paresthesias in the left arm and leg, aslo the neck and lower face.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Paraesthesia, Red blood cell sedimentation rate normal, Vitamin B12 normal
Clinical narrative: Developed paresthesias (numbness and tingling). Initially in the right arm x 1 day on 4/1. Subsequently developed more persistent parestheias in the right lower extremity on 4/14. Had similar lower extremity paresthesias in the past, but these were brief and never persisted. Over the next week developed paresthesias in the left arm and leg, aslo the neck and lower face.
Age: 42.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Fatigue, Haematuria, Headache, Myalgia, Pyrexia
Clinical narrative: a significant amount of blood in my urine; blood in my urine is getting worse and appears that I am urinating completely blood.; body aches; fever; chills; This is a spontaneous report from a contactable consumer or other non hcp (Patient). A 42-years-old non-pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot Number: FF2587), second dose via an unspecified route of administration, administered in Arm Left on 22Sep2021 16:00 (at the age of 42 year) as DOSE 2, SINGLE for covid-19 immunization. Medical history included IgA nephropathy from an unknown date and unknown if ongoing (I have a history of IgA Nephropathy that has been very stable for over 7 years with normal kidney function). The patient previously took Levaquin and experienced drug allergy. Historical vaccine included bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot Number: FC3183), first dose via an unspecified route of administration, administered in Arm Left on 02Sep2021 16:30 (at the age of 42 year) as DOSE 1, SINGLE for covid-19 immunization. The patient concomitant medications were not reported. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Patient was not diagnosed with COVID-19, prior vaccination and since the vaccination. On 22Sep2021 21:00 within hours of receiving the second injection patient began have a significant amount of blood in my urine as well as the common symptoms body aches, fever, & chills. The common symptoms have eased up but the blood in my urine is getting worse and appears that patient was urinating completely blood. Case was considered as non-Serious. Adverse event resulted in doctor or other healthcare professional office/clinic visit. Patient was currently awaiting a referral to re-establish with a nephrologist per recommendation of Primary Care physician. The outcome of the event a significant amount of blood in my urine and blood in my urine is getting worse and appears that urinating completely blood was Not Recovered. The events body aches, fever and chills was recovered on unspecified date of September 2021.    No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Urine analysis
Clinical narrative: a significant amount of blood in my urine; blood in my urine is getting worse and appears that I am urinating completely blood.; body aches; fever; chills; This is a spontaneous report from a contactable consumer or other non hcp (Patient). A 42-years-old non-pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot Number: FF2587), second dose via an unspecified route of administration, administered in Arm Left on 22Sep2021 16:00 (at the age of 42 year) as DOSE 2, SINGLE for covid-19 immunization. Medical history included IgA nephropathy from an unknown date and unknown if ongoing (I have a history of IgA Nephropathy that has been very stable for over 7 years with normal kidney function). The patient previously took Levaquin and experienced drug allergy. Historical vaccine included bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot Number: FC3183), first dose via an unspecified route of administration, administered in Arm Left on 02Sep2021 16:30 (at the age of 42 year) as DOSE 1, SINGLE for covid-19 immunization. The patient concomitant medications were not reported. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Patient was not diagnosed with COVID-19, prior vaccination and since the vaccination. On 22Sep2021 21:00 within hours of receiving the second injection patient began have a significant amount of blood in my urine as well as the common symptoms body aches, fever, & chills. The common symptoms have eased up but the blood in my urine is getting worse and appears that patient was urinating completely blood. Case was considered as non-Serious. Adverse event resulted in doctor or other healthcare professional office/clinic visit. Patient was currently awaiting a referral to re-establish with a nephrologist per recommendation of Primary Care physician. The outcome of the event a significant amount of blood in my urine and blood in my urine is getting worse and appears that urinating completely blood was Not Recovered. The events body aches, fever and chills was recovered on unspecified date of September 2021.    No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Blood urine present, Chills, Condition aggravated, Pain, Pyrexia
Clinical narrative: a significant amount of blood in my urine; blood in my urine is getting worse and appears that I am urinating completely blood.; body aches; fever; chills; This is a spontaneous report from a contactable consumer or other non hcp (Patient). A 42-years-old non-pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot Number: FF2587), second dose via an unspecified route of administration, administered in Arm Left on 22Sep2021 16:00 (at the age of 42 year) as DOSE 2, SINGLE for covid-19 immunization. Medical history included IgA nephropathy from an unknown date and unknown if ongoing (I have a history of IgA Nephropathy that has been very stable for over 7 years with normal kidney function). The patient previously took Levaquin and experienced drug allergy. Historical vaccine included bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot Number: FC3183), first dose via an unspecified route of administration, administered in Arm Left on 02Sep2021 16:30 (at the age of 42 year) as DOSE 1, SINGLE for covid-19 immunization. The patient concomitant medications were not reported. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Patient was not diagnosed with COVID-19, prior vaccination and since the vaccination. On 22Sep2021 21:00 within hours of receiving the second injection patient began have a significant amount of blood in my urine as well as the common symptoms body aches, fever, & chills. The common symptoms have eased up but the blood in my urine is getting worse and appears that patient was urinating completely blood. Case was considered as non-Serious. Adverse event resulted in doctor or other healthcare professional office/clinic visit. Patient was currently awaiting a referral to re-establish with a nephrologist per recommendation of Primary Care physician. The outcome of the event a significant amount of blood in my urine and blood in my urine is getting worse and appears that urinating completely blood was Not Recovered. The events body aches, fever and chills was recovered on unspecified date of September 2021.    No follow-up attempts are needed. No further information is expected.
Age: 67.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Patient is a 68 y.o. male with a PMH significant for COVID (10/02/21), CAD (s/p stents 2016, s/p left CEA 2019), CKD, HTN and HLD who presents to ED as a transfer for worsening hypoxic respiratory failure. Of note, contact information of providers who cared for the patient at Hospital is not available in the electronic health record.   Patient was diagnosed with COVID 19 on 10/02/21 which was treated outpatient with supplemental oxygen over the last month. Patient was able to wean his O2 to 4L/NC until a few days ago. On admission patient on 8-10L NC at home with oxygen saturation no better than 90%. On arrival to ED patient was alert but hypoxic with initial work up significant for small subsegmental PE on CTA, elevated troponins, leukocytosis, AKI on CKD and elevated CRP. He was admitted and started on therapeutic lovenox, levaquin and steroids. He continued to have increasing oxygen requirements and was placed on HFNC 100% 30L. ICU was consulted for transfer to higher level of care per family request.   Upon exam, patient is intubated and sedated on 100% on the vent. There is no family available so history has been taken from the chart.   #Sequela of COVID 19 vs. Interstitial Pneumonitis (NSIP pattern)  COVID + diagnosis 10/02/21 Home on  4L/NC at home since COVID diagnosis. -was initially admitted to ICU and required intubation.  11/22: CT chest:  Extensive areas of groundglass attenuation involving both lungs. The lungs appear lesser radiographically dense than on 11/4/2021, although worse than on 10/2/2021.  Completed Zosyn 11/10/21 Continue steroid taper (60mg x7 days, 50mg x7 days, 40mg x7 days, 30mg x7 days, 20mg x7 days, 10mg x7 days). Currently on prednisone 30 mg daily, Outpatient pulm follow up.  encourage incentive spirometry Q 1hrs, chest physiotherapy scheduled. discontinued duoneb since pt does not feel much significant improvement and had sinus tachycardias.   Discharge Disposition/Condition Disposition: (rehab facility) Condition: Stable (s/sx potential problems absent or manageable)
Age: 67.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Acute kidney injury, Angiogram pulmonary abnormal, C-reactive protein increased, COVID-19, Chronic kidney disease
Clinical narrative: Patient is a 68 y.o. male with a PMH significant for COVID (10/02/21), CAD (s/p stents 2016, s/p left CEA 2019), CKD, HTN and HLD who presents to ED as a transfer for worsening hypoxic respiratory failure. Of note, contact information of providers who cared for the patient at Hospital is not available in the electronic health record.   Patient was diagnosed with COVID 19 on 10/02/21 which was treated outpatient with supplemental oxygen over the last month. Patient was able to wean his O2 to 4L/NC until a few days ago. On admission patient on 8-10L NC at home with oxygen saturation no better than 90%. On arrival to ED patient was alert but hypoxic with initial work up significant for small subsegmental PE on CTA, elevated troponins, leukocytosis, AKI on CKD and elevated CRP. He was admitted and started on therapeutic lovenox, levaquin and steroids. He continued to have increasing oxygen requirements and was placed on HFNC 100% 30L. ICU was consulted for transfer to higher level of care per family request.   Upon exam, patient is intubated and sedated on 100% on the vent. There is no family available so history has been taken from the chart.   #Sequela of COVID 19 vs. Interstitial Pneumonitis (NSIP pattern)  COVID + diagnosis 10/02/21 Home on  4L/NC at home since COVID diagnosis. -was initially admitted to ICU and required intubation.  11/22: CT chest:  Extensive areas of groundglass attenuation involving both lungs. The lungs appear lesser radiographically dense than on 11/4/2021, although worse than on 10/2/2021.  Completed Zosyn 11/10/21 Continue steroid taper (60mg x7 days, 50mg x7 days, 40mg x7 days, 30mg x7 days, 20mg x7 days, 10mg x7 days). Currently on prednisone 30 mg daily, Outpatient pulm follow up.  encourage incentive spirometry Q 1hrs, chest physiotherapy scheduled. discontinued duoneb since pt does not feel much significant improvement and had sinus tachycardias.   Discharge Disposition/Condition Disposition: (rehab facility) Condition: Stable (s/sx potential problems absent or manageable)
Age: 67.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Computerised tomogram thorax abnormal, Condition aggravated, Endotracheal intubation, Intensive care, Interstitial lung disease
Clinical narrative: Patient is a 68 y.o. male with a PMH significant for COVID (10/02/21), CAD (s/p stents 2016, s/p left CEA 2019), CKD, HTN and HLD who presents to ED as a transfer for worsening hypoxic respiratory failure. Of note, contact information of providers who cared for the patient at Hospital is not available in the electronic health record.   Patient was diagnosed with COVID 19 on 10/02/21 which was treated outpatient with supplemental oxygen over the last month. Patient was able to wean his O2 to 4L/NC until a few days ago. On admission patient on 8-10L NC at home with oxygen saturation no better than 90%. On arrival to ED patient was alert but hypoxic with initial work up significant for small subsegmental PE on CTA, elevated troponins, leukocytosis, AKI on CKD and elevated CRP. He was admitted and started on therapeutic lovenox, levaquin and steroids. He continued to have increasing oxygen requirements and was placed on HFNC 100% 30L. ICU was consulted for transfer to higher level of care per family request.   Upon exam, patient is intubated and sedated on 100% on the vent. There is no family available so history has been taken from the chart.   #Sequela of COVID 19 vs. Interstitial Pneumonitis (NSIP pattern)  COVID + diagnosis 10/02/21 Home on  4L/NC at home since COVID diagnosis. -was initially admitted to ICU and required intubation.  11/22: CT chest:  Extensive areas of groundglass attenuation involving both lungs. The lungs appear lesser radiographically dense than on 11/4/2021, although worse than on 10/2/2021.  Completed Zosyn 11/10/21 Continue steroid taper (60mg x7 days, 50mg x7 days, 40mg x7 days, 30mg x7 days, 20mg x7 days, 10mg x7 days). Currently on prednisone 30 mg daily, Outpatient pulm follow up.  encourage incentive spirometry Q 1hrs, chest physiotherapy scheduled. discontinued duoneb since pt does not feel much significant improvement and had sinus tachycardias.   Discharge Disposition/Condition Disposition: (rehab facility) Condition: Stable (s/sx potential problems absent or manageable)
Age: 67.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Leukocytosis, Lung opacity, Mechanical ventilation, Pulmonary embolism, Respiratory failure
Clinical narrative: Patient is a 68 y.o. male with a PMH significant for COVID (10/02/21), CAD (s/p stents 2016, s/p left CEA 2019), CKD, HTN and HLD who presents to ED as a transfer for worsening hypoxic respiratory failure. Of note, contact information of providers who cared for the patient at Hospital is not available in the electronic health record.   Patient was diagnosed with COVID 19 on 10/02/21 which was treated outpatient with supplemental oxygen over the last month. Patient was able to wean his O2 to 4L/NC until a few days ago. On admission patient on 8-10L NC at home with oxygen saturation no better than 90%. On arrival to ED patient was alert but hypoxic with initial work up significant for small subsegmental PE on CTA, elevated troponins, leukocytosis, AKI on CKD and elevated CRP. He was admitted and started on therapeutic lovenox, levaquin and steroids. He continued to have increasing oxygen requirements and was placed on HFNC 100% 30L. ICU was consulted for transfer to higher level of care per family request.   Upon exam, patient is intubated and sedated on 100% on the vent. There is no family available so history has been taken from the chart.   #Sequela of COVID 19 vs. Interstitial Pneumonitis (NSIP pattern)  COVID + diagnosis 10/02/21 Home on  4L/NC at home since COVID diagnosis. -was initially admitted to ICU and required intubation.  11/22: CT chest:  Extensive areas of groundglass attenuation involving both lungs. The lungs appear lesser radiographically dense than on 11/4/2021, although worse than on 10/2/2021.  Completed Zosyn 11/10/21 Continue steroid taper (60mg x7 days, 50mg x7 days, 40mg x7 days, 30mg x7 days, 20mg x7 days, 10mg x7 days). Currently on prednisone 30 mg daily, Outpatient pulm follow up.  encourage incentive spirometry Q 1hrs, chest physiotherapy scheduled. discontinued duoneb since pt does not feel much significant improvement and had sinus tachycardias.   Discharge Disposition/Condition Disposition: (rehab facility) Condition: Stable (s/sx potential problems absent or manageable)
Age: 67.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: SARS-CoV-2 test positive, Sinus tachycardia, Troponin increased
Clinical narrative: Patient is a 68 y.o. male with a PMH significant for COVID (10/02/21), CAD (s/p stents 2016, s/p left CEA 2019), CKD, HTN and HLD who presents to ED as a transfer for worsening hypoxic respiratory failure. Of note, contact information of providers who cared for the patient at Hospital is not available in the electronic health record.   Patient was diagnosed with COVID 19 on 10/02/21 which was treated outpatient with supplemental oxygen over the last month. Patient was able to wean his O2 to 4L/NC until a few days ago. On admission patient on 8-10L NC at home with oxygen saturation no better than 90%. On arrival to ED patient was alert but hypoxic with initial work up significant for small subsegmental PE on CTA, elevated troponins, leukocytosis, AKI on CKD and elevated CRP. He was admitted and started on therapeutic lovenox, levaquin and steroids. He continued to have increasing oxygen requirements and was placed on HFNC 100% 30L. ICU was consulted for transfer to higher level of care per family request.   Upon exam, patient is intubated and sedated on 100% on the vent. There is no family available so history has been taken from the chart.   #Sequela of COVID 19 vs. Interstitial Pneumonitis (NSIP pattern)  COVID + diagnosis 10/02/21 Home on  4L/NC at home since COVID diagnosis. -was initially admitted to ICU and required intubation.  11/22: CT chest:  Extensive areas of groundglass attenuation involving both lungs. The lungs appear lesser radiographically dense than on 11/4/2021, although worse than on 10/2/2021.  Completed Zosyn 11/10/21 Continue steroid taper (60mg x7 days, 50mg x7 days, 40mg x7 days, 30mg x7 days, 20mg x7 days, 10mg x7 days). Currently on prednisone 30 mg daily, Outpatient pulm follow up.  encourage incentive spirometry Q 1hrs, chest physiotherapy scheduled. discontinued duoneb since pt does not feel much significant improvement and had sinus tachycardias.   Discharge Disposition/Condition Disposition: (rehab facility) Condition: Stable (s/sx potential problems absent or manageable)
Age: 27.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Blood test, Cardiac stress test, Chest discomfort, Chest pain, Diarrhoea
Clinical narrative: PALPITATIONS, CHEST PAIN
Age: 27.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Echocardiogram, Electrocardiogram, Fatigue, Palpitations, Sinus tachycardia
Clinical narrative: PALPITATIONS, CHEST PAIN
Age: 27.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Troponin, X-ray
Clinical narrative: PALPITATIONS, CHEST PAIN
Age: 27.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Angiogram, Blood test, Chest X-ray, Chest pain, Palpitations
Clinical narrative: PALPITATIONS, CHEST PAIN
Age: 80.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Death, Vaccine breakthrough infection
Clinical narrative: PMH:  CHF, COPD, MI, HTN, prostate CA, end-stage renal failure; pt to ED and c/o SOB for several days; diagnosed positive for COVID  wk before coming to ED; became hypotensive; ICU; DNAR; Vasopressin and levophed; attempted to place arterial line but unable to place line; pt's condition worsened and pt died in the hospital
Age: 80.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Death, Dyspnoea, Hypotension, Intensive care
Clinical narrative: PMH:  CHF, COPD, MI, HTN, prostate CA, end-stage renal failure; pt to ED and c/o SOB for several days; diagnosed positive for COVID  wk before coming to ED; became hypotensive; ICU; DNAR; Vasopressin and levophed; attempted to place arterial line but unable to place line; pt's condition worsened and pt died in the hospital
Age: 80.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: SARS-CoV-2 test positive
Clinical narrative: PMH:  CHF, COPD, MI, HTN, prostate CA, end-stage renal failure; pt to ED and c/o SOB for several days; diagnosed positive for COVID  wk before coming to ED; became hypotensive; ICU; DNAR; Vasopressin and levophed; attempted to place arterial line but unable to place line; pt's condition worsened and pt died in the hospital
Age: 85.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Asymptomatic COVID-19, Hip fracture, SARS-CoV-2 test positive
Clinical narrative: tested positive for COVID. He was testing in the setting of screening of multiple patients due to possible exposures on the unit from a known individual that was COVID +.  He remains asymptomatic. Would be considered a candidate for monoclonal antibody base on his age and CAD history but no indication for initiation at this time.
Age: 85.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Asymptomatic COVID-19, SARS-CoV-2 test positive
Clinical narrative: tested positive for COVID. He was testing in the setting of screening of multiple patients due to possible exposures on the unit from a known individual that was COVID +.  He remains asymptomatic. Would be considered a candidate for monoclonal antibody base on his age and CAD history but no indication for initiation at this time.
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Neuralgia, Pain in extremity
Clinical narrative: blood pressure as really high; After receiving the 2nd dose, muscle pain has worsened; reports her leg muscles are stiffening and she cant straighten the leg up; After receiving the 2nd dose, muscle pain has worsened; reports her leg muscles are stiffening and she cant straighten the leg up; After receiving the 2nd dose, muscle pain has worsened; reports her leg muscles are stiffening and she cant straighten the leg up; burning in the leg; extreme pain in her right leg; unable to walk; She had pain in her arm that she received the vaccine in; This is a spontaneous report from a Pfizer sponsored program from a contactable consumer (patient) via medical information team.    A 56-year-old female patient received the second dose of bnt162b2 (COMIRNATY, solution for injection, Lot number: not reported), via an unspecified route of administration on 14Nov2021 as dose 2, single for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient's medical history and concomitant medication was not reported. The patient received her first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 m-RNA VACCINE, Solution for injection, Lot number: not reported) via an unspecified route of administration on 16Oct2021 as dose 1, single for COVID-19 immunisation and she developed intermittent muscle pain 4 days after her first dose. On an unspecified date in Nov2021, the patient experienced after receiving the second dose, muscle pain had worsened and her leg muscles were stiffening, could not straighten the leg up and had burning in the leg. The patient had extreme pain in her right leg and unable to walk on it and also her blood pressure was really high. The patient also had pain in her arm that she received the vaccine in. The patient had seen her doctor twice, had tests done and blood clot was ruled out. She felt that this was from receiving the vaccine, and she was wanting to know what she could take for the pain. The patient stated that the pain was in her right leg. She has been taking Naproxen which was prescribed to her by the doctor. Sometimes the pain was all in the back of her leg. The patient reported that that it was like all form the vaccine went to her leg instead of going throughout her whole body like it was supposed to. The patient could not straighten her leg, all her muscles were stiffening up. Therapeutic measures were taken as a result of extreme pain in her right leg (pain in extremity). On an unspecified date in Nov2021, the patient underwent lab tests and procedures which included blood pressure measurement: high and blood test: unknown, blood clot was ruled out. The clinical outcome of event muscle pain was not recovered and the other events was unknown.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Blood pressure measurement, Blood test, Burning sensation, Condition aggravated, Gait inability
Clinical narrative: blood pressure as really high; After receiving the 2nd dose, muscle pain has worsened; reports her leg muscles are stiffening and she cant straighten the leg up; After receiving the 2nd dose, muscle pain has worsened; reports her leg muscles are stiffening and she cant straighten the leg up; After receiving the 2nd dose, muscle pain has worsened; reports her leg muscles are stiffening and she cant straighten the leg up; burning in the leg; extreme pain in her right leg; unable to walk; She had pain in her arm that she received the vaccine in; This is a spontaneous report from a Pfizer sponsored program from a contactable consumer (patient) via medical information team.    A 56-year-old female patient received the second dose of bnt162b2 (COMIRNATY, solution for injection, Lot number: not reported), via an unspecified route of administration on 14Nov2021 as dose 2, single for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient's medical history and concomitant medication was not reported. The patient received her first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 m-RNA VACCINE, Solution for injection, Lot number: not reported) via an unspecified route of administration on 16Oct2021 as dose 1, single for COVID-19 immunisation and she developed intermittent muscle pain 4 days after her first dose. On an unspecified date in Nov2021, the patient experienced after receiving the second dose, muscle pain had worsened and her leg muscles were stiffening, could not straighten the leg up and had burning in the leg. The patient had extreme pain in her right leg and unable to walk on it and also her blood pressure was really high. The patient also had pain in her arm that she received the vaccine in. The patient had seen her doctor twice, had tests done and blood clot was ruled out. She felt that this was from receiving the vaccine, and she was wanting to know what she could take for the pain. The patient stated that the pain was in her right leg. She has been taking Naproxen which was prescribed to her by the doctor. Sometimes the pain was all in the back of her leg. The patient reported that that it was like all form the vaccine went to her leg instead of going throughout her whole body like it was supposed to. The patient could not straighten her leg, all her muscles were stiffening up. Therapeutic measures were taken as a result of extreme pain in her right leg (pain in extremity). On an unspecified date in Nov2021, the patient underwent lab tests and procedures which included blood pressure measurement: high and blood test: unknown, blood clot was ruled out. The clinical outcome of event muscle pain was not recovered and the other events was unknown.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Hypertension, Musculoskeletal stiffness, Myalgia, Pain in extremity
Clinical narrative: blood pressure as really high; After receiving the 2nd dose, muscle pain has worsened; reports her leg muscles are stiffening and she cant straighten the leg up; After receiving the 2nd dose, muscle pain has worsened; reports her leg muscles are stiffening and she cant straighten the leg up; After receiving the 2nd dose, muscle pain has worsened; reports her leg muscles are stiffening and she cant straighten the leg up; burning in the leg; extreme pain in her right leg; unable to walk; She had pain in her arm that she received the vaccine in; This is a spontaneous report from a Pfizer sponsored program from a contactable consumer (patient) via medical information team.    A 56-year-old female patient received the second dose of bnt162b2 (COMIRNATY, solution for injection, Lot number: not reported), via an unspecified route of administration on 14Nov2021 as dose 2, single for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient's medical history and concomitant medication was not reported. The patient received her first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 m-RNA VACCINE, Solution for injection, Lot number: not reported) via an unspecified route of administration on 16Oct2021 as dose 1, single for COVID-19 immunisation and she developed intermittent muscle pain 4 days after her first dose. On an unspecified date in Nov2021, the patient experienced after receiving the second dose, muscle pain had worsened and her leg muscles were stiffening, could not straighten the leg up and had burning in the leg. The patient had extreme pain in her right leg and unable to walk on it and also her blood pressure was really high. The patient also had pain in her arm that she received the vaccine in. The patient had seen her doctor twice, had tests done and blood clot was ruled out. She felt that this was from receiving the vaccine, and she was wanting to know what she could take for the pain. The patient stated that the pain was in her right leg. She has been taking Naproxen which was prescribed to her by the doctor. Sometimes the pain was all in the back of her leg. The patient reported that that it was like all form the vaccine went to her leg instead of going throughout her whole body like it was supposed to. The patient could not straighten her leg, all her muscles were stiffening up. Therapeutic measures were taken as a result of extreme pain in her right leg (pain in extremity). On an unspecified date in Nov2021, the patient underwent lab tests and procedures which included blood pressure measurement: high and blood test: unknown, blood clot was ruled out. The clinical outcome of event muscle pain was not recovered and the other events was unknown.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Gait disturbance, Hypoaesthesia, Musculoskeletal stiffness
Clinical narrative: blood pressure as really high; After receiving the 2nd dose, muscle pain has worsened; reports her leg muscles are stiffening and she cant straighten the leg up; After receiving the 2nd dose, muscle pain has worsened; reports her leg muscles are stiffening and she cant straighten the leg up; After receiving the 2nd dose, muscle pain has worsened; reports her leg muscles are stiffening and she cant straighten the leg up; burning in the leg; extreme pain in her right leg; unable to walk; She had pain in her arm that she received the vaccine in; This is a spontaneous report from a Pfizer sponsored program from a contactable consumer (patient) via medical information team.    A 56-year-old female patient received the second dose of bnt162b2 (COMIRNATY, solution for injection, Lot number: not reported), via an unspecified route of administration on 14Nov2021 as dose 2, single for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient's medical history and concomitant medication was not reported. The patient received her first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 m-RNA VACCINE, Solution for injection, Lot number: not reported) via an unspecified route of administration on 16Oct2021 as dose 1, single for COVID-19 immunisation and she developed intermittent muscle pain 4 days after her first dose. On an unspecified date in Nov2021, the patient experienced after receiving the second dose, muscle pain had worsened and her leg muscles were stiffening, could not straighten the leg up and had burning in the leg. The patient had extreme pain in her right leg and unable to walk on it and also her blood pressure was really high. The patient also had pain in her arm that she received the vaccine in. The patient had seen her doctor twice, had tests done and blood clot was ruled out. She felt that this was from receiving the vaccine, and she was wanting to know what she could take for the pain. The patient stated that the pain was in her right leg. She has been taking Naproxen which was prescribed to her by the doctor. Sometimes the pain was all in the back of her leg. The patient reported that that it was like all form the vaccine went to her leg instead of going throughout her whole body like it was supposed to. The patient could not straighten her leg, all her muscles were stiffening up. Therapeutic measures were taken as a result of extreme pain in her right leg (pain in extremity). On an unspecified date in Nov2021, the patient underwent lab tests and procedures which included blood pressure measurement: high and blood test: unknown, blood clot was ruled out. The clinical outcome of event muscle pain was not recovered and the other events was unknown.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
Age: 31.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Asthenia, Blood test, Burning sensation, Chronic fatigue syndrome, Cytomegalovirus infection
Clinical narrative: reactivation CMV infection, chronic fatigue, depression/anxiety
Age: 31.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Disturbance in attention, Fatigue, Hypoaesthesia, Insomnia, Loss of employment
Clinical narrative: reactivation CMV infection, chronic fatigue, depression/anxiety
Age: 31.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Malaise, Muscle atrophy, Muscle twitching, Muscular weakness, Pain
Clinical narrative: reactivation CMV infection, chronic fatigue, depression/anxiety
Age: 31.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Vertigo, Vestibular disorder, Weight decreased
Clinical narrative: reactivation CMV infection, chronic fatigue, depression/anxiety
Age: 31.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Arthralgia, Balance disorder, Burning sensation, Dysgeusia, Ear disorder
Clinical narrative: reactivation CMV infection, chronic fatigue, depression/anxiety
Age: 31.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Fatigue, Feeling abnormal, Hypoaesthesia, Insomnia, Malaise
Clinical narrative: reactivation CMV infection, chronic fatigue, depression/anxiety
Age: 31.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Muscle atrophy, Muscular weakness, Palpitations, Paraesthesia, SARS-CoV-2 test
Clinical narrative: reactivation CMV infection, chronic fatigue, depression/anxiety